“A higher proportion of patients showed a headache response at two hours postdose in the 10-mg, 20-mg, 30-mg, and 45-mg COL-144 dose groups, compared with placebo—54.2% to 75% versus 45.2%—with a statistically significant linear association between response rates and dose levels.”
Regarding secondary end points of sustained response, pain free, disability, use of rescue medication, associated symptoms, and patient global impression, greater improvements versus placebo were observed for the 20- and 30-mg doses.
“COL-144 was well tolerated,” Dr. Pilgrim commented. “There were no clinically significant abnormalities of any safety monitoring parameters—that is, heart rate, blood pressure, 12-lead ECG, hematology, biochemistry, and urine analysis following administration of COL-144.
“Selective 5-HT1F agonists may offer an alternative means to treat acute migraine attacks without the cardiovascular risk associated with triptans,” Dr. Pilgrim added. “Furthermore, the neuronal site of action may offer efficacy advantages that will be explored further in future studies.”
—Colby Stong